Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation

✍ Scribed by Montserrat Garcia-Retortillo; Xavier Forns; Josep M. Llovet; Miquel Navasa; Anna Feliu; Anna Massaguer; Miquel Bruguera; Josep Fuster; Juan Carlos Garcia-Valdecasas; Antoni Rimola

• Publisher: John Wiley and Sons
• Year: 2004
• Tongue: English
• Weight: 197 KB
• Volume: 40
• Category: Article
• ISSN: 0270-9139
• DOI: 10.1002/hep.20357

✦ Synopsis

Preliminary reports suggested that hepatitis C virus (HCV) infection has a more aggressive course following living donor liver transplantation (LDLT) compared to cadaveric liver transplantation (CLT). The aim of this prospective study was to establish if HCV disease recurrence differs between LDLT and CLT. A cohort of 116 consecutive HCV-infected patients undergoing 117 LTs in a single center from March 2000 to August 2003 were followed-up, including systematic liver biopsies. Severe recurrence (SR) was defined as biopsy-proven cirrhosis and/or the occurrence of clinical decompensation. After a median follow-up of 22 months (2.6 -44 months), 26 (22%) patients developed SR (decompensation in 12), involving 17 (18%) of 95 patients undergoing CLT and 9 (41%) of 22 undergoing LDLT. The 2-year probability of presenting SR was significantly higher in LDLT compared to CLT (45% vs. 22%, P ‫؍‬ .019). By univariate analysis LDLT (P ‫؍‬ .019) and an ALT higher than 80 IU/L 3 months after LT (P ‫؍‬ .022) were predictors of SR. In 93 patients from whom a liver biopsy was available 3 months after LT, a lobular necroinflammatory score >1 (P < .01), LDLT (P < .01), and biliary complications (P ‫؍‬ .046) were associated with SR. However, the only variables independently associated with SR were LDLT (odds ratio [OR], ‫؍‬ 2.8; 95% CI,1.19-6.6; P ‫؍‬ .024) and a lobular necroinflammatory score >1 (OR, 3.1; 95% CI, 1.2-8; P ‫؍‬ .013). In conclusion, HCV recurrence is more severe in LDLT compared to CLT. Although our results were based on a single-center experience, they should be considered in the decision-making process of transplant programs, since severe HCV recurrence may ultimately compromise graft and patient survival. (HEPATOLOGY 2004;